Tell your U.S. senators: Pass health care price transparency
High cost of Xtandi, treatment for prostate cancer, could be solved using “March-In” rights
Federal government is urged to take action on drug prices for key treatment for prostate cancer
It's been one year since four patients living with prostate cancer asked the federal government to use its "March-In" rights to bring down the costs of Xtandi. We're still waiting for an answer. PIRG followed up with this request.
Downloads
Topics
Authors
Patricia Kelmar
Senior Director, Health Care Campaigns, PIRG
Patricia directs the health care campaign work for U.S. PIRG and provides support to our state offices for state-based health initiatives. Her prior roles include senior policy advisor at NJ Health Care Quality Institute, associate state director at AARP New Jersey and consumer advocate at NJPIRG. She was appointed to the Ground Ambulance and Patient Billing Advisory Committee in 2022 and works with patient advocates across the U.S. Patricia enjoys walking along the Potomac River and sharing her love of books with friends and family around the world.
Find Out More
Outpatient outrage: Hospitals charge fees for care at the doctor’s office
PIRG joins open letter to Congress calling for “Same service, same price” policy
Hill Letter to US House: Vote “Yes” on Lower Costs, More Transparency
